Verrica Pharmaceuticals

Yahoo Finance • 19 days ago

Verrica Pharmaceuticals Q4 Earnings Call Highlights

Verrica Pharmaceuticals logo Key Points YCANTH commercial momentum: Revenue grew >130% in 2025 with Q4 net YCANTH revenue of $3.7 million, dispensed applicator units nearly doubled to 51,196 for the year, and inventory is "normalized" af... Full story

Yahoo Finance • 4 months ago

Verrica Pharmaceuticals announces $50M PIPE financing

* Verrica Pharmaceuticals (VRCA [https://seekingalpha.com/symbol/VRCA]) said it has signed securities purchase agreements for a private investment in public equity (PIPE) that will raise about $50 million in gross proceeds before fees.... Full story

Yahoo Finance • 4 months ago

Verrica targets European expansion for YCANTH as Phase III programs advance and sales force grows

Earnings Call Insights: Verrica Pharmaceuticals (VRCA) Q3 2025 MANAGEMENT VIEW * Jayson Rieger, President and CEO, highlighted several commercial, corporate, scientific, and regulatory milestones, emphasizing, "we've advanced our clini... Full story

Yahoo Finance • 4 months ago

Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M

* Verrica Pharmaceuticals press release [https://seekingalpha.com/pr/20308644-verrica-pharmaceuticals-reports-third-quarter-2025-financial-results] (VRCA [https://seekingalpha.com/symbol/VRCA]): Q3 Non-GAAP EPS of $0.13. * Revenue of $... Full story

Yahoo Finance • 4 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design... Full story

Yahoo Finance • 5 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additiona... Full story

Yahoo Finance • 6 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today... Full story

Yahoo Finance • 6 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in... Full story

Yahoo Finance • 8 months ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Compl... Full story

Yahoo Finance • 8 months ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • 9 months ago

Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales

WEST CHESTER, Pa. - Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a pharmaceutical company with a market capitalization of approximately $80 million, dispensed a record 13,434 units of its YCANTH applicators in the second quarter of 2025, re... Full story

Yahoo Finance • last year

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclose... Full story

Yahoo Finance • last year

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • last year

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of... Full story

Yahoo Finance • last year

Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) stands against the other Worst 52-Week Lo... Full story

Yahoo Finance • 2 years ago

Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers?

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) stands against the other worst 52-week low... Full story

Yahoo Finance • 2 years ago

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

WEST CHESTER, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • 2 years ago

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 a... Full story

Yahoo Finance • 2 years ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, t... Full story

Yahoo Finance • 3 years ago

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions,... Full story